Tatiana V. Popkova

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries.

Journal: The Lancet. Rheumatology

Published: June 01, 2025

Reply to Saleh, C.; Budincevic, H. Interleukin-6, Tocilizumab and Atherosclerosis. Comment on "Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2024, 25, 12425".

Reply to Saleh, C.; Budincevic, H. Interleukin-6, Tocilizumab and Atherosclerosis. Comment on "Gerasimova et al. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2024, 25, 12425".

Journal: International journal of molecular sciences

Published: February 17, 2025

Type 2 diabetes mellitus in rheumatoid arthritis and systemic lupus erythematosus: A review

Type 2 diabetes mellitus in rheumatoid arthritis and systemic lupus erythematosus: A review

Journal: Terapevticheskii arkhiv

Published: February 11, 2025

Immunophenotypes of Systemic Lupus Erythematosus-Features of Clinical and Laboratory Disorders.

Immunophenotypes of Systemic Lupus Erythematosus-Features of Clinical and Laboratory Disorders.

Journal: Doklady. Biochemistry and biophysics

Published: February 03, 2025

Dynamics of Modified Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis on the Background of 5-Year Therapy with an Interleukin 6 Receptor Inhibitor.

Dynamics of Modified Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis on the Background of 5-Year Therapy with an Interleukin 6 Receptor Inhibitor.

Journal: Doklady. Biochemistry and biophysics

Published: February 02, 2025

Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.

Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis.

Journal: International journal of molecular sciences

Published: October 09, 2024

Inflammatory Response of Monocytes/Macrophages in Patients with Systemic Sclerosis.

Inflammatory Response of Monocytes/Macrophages in Patients with Systemic Sclerosis.

Journal: Frontiers in bioscience (Landmark edition)

Published: May 20, 2024

The effect of hypothyroidism on cardiovascular events and type 2 diabetes mellitus developing in rheumatoid arthritis

The effect of hypothyroidism on cardiovascular events and type 2 diabetes mellitus developing in rheumatoid arthritis

Journal: Terapevticheskii arkhiv

Published: May 15, 2024

Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases.

Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases.

Journal: Doklady. Biochemistry and biophysics

Published: April 05, 2024

Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases.

Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases.

Journal: Doklady. Biochemistry and biophysics

Published: April 04, 2024

Hyperleptinemia as a Marker of Various Phenotypes of Obesity and Overweight in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Hyperleptinemia as a Marker of Various Phenotypes of Obesity and Overweight in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Journal: Doklady. Biochemistry and biophysics

Published: April 03, 2024

Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries.

Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries.

Journal: The Lancet. Rheumatology

Published: February 18, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026